HomeFilePharmacology

Pharmacology

ADAPT-DES: Proton Pump Inhibitors and Clopidogrel in Patients with DES

Original Title: Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients. The...

Prasugrel in the Treatment of Clopidogrel Nonresponders Undergoing PCI

Original Title: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention (RECLOSE-3 study). Reference: Valenti R, et al. JACC...

DAPT Substudy: Score to Personalize Optimal Dual Antiaggregation Therapy Duration

Original Title: Individualizing Treatment Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Analysis from the...

SPRINT: lower blood pressure targets for many hypertensive

Original Title: A randomized trial of intensive versus standard blood-pressure control. Presenter: Wright JR Jr. A systolic blood-pressure target...

PEGASUS-TIMI 54 Subanalysis: Discontinuation of Ticagrelor Mostly Due to Dyspnea or Bleeding

Original Title: Long-term tolerability of ticagrelor for secondary prevention: insights from PEGASUS-TIMI 54 trial. Presenter: Bonaca MP. The higher...

JUPITER Subanalysis: Reduction of LDL Determines Clinical Impact of Rosuvastatin Therapy

Original Title: Cholesterol treatment targets and clinical outcomes: a JUPITER trial update. Presenter: Paul Ridker. The lower the LDL...

Meta-analysis of prolonged DAT after DES

Extending the antiaggregation therapy over a year reduces adverse events in patients with a history of AMI,...

Risks and benefits of extending dual antiplatelet therapy in patients with and without MI

Original title: Benefits and Risks of Extended Duration Dual Antiplatelet Therapy after PCI in Patients With and Without...